Financial Enhancement Group LLC Makes New $6.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)

Financial Enhancement Group LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 18,616 shares of the biotechnology company's stock, valued at approximately $6,671,000. United Therapeutics makes up about 1.2% of Financial Enhancement Group LLC's portfolio, making the stock its 27th largest position.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Renaissance Technologies LLC raised its stake in shares of United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock valued at $692,748,000 after acquiring an additional 22,978 shares in the last quarter. LSV Asset Management raised its stake in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock worth $307,837,000 after buying an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in United Therapeutics by 4.0% in the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company's stock worth $186,656,000 after buying an additional 22,683 shares in the last quarter. Pacer Advisors Inc. raised its stake in United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock worth $178,972,000 after buying an additional 92,240 shares in the last quarter. Finally, Swedbank AB bought a new position in United Therapeutics in the first quarter worth approximately $97,316,000. Institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. TD Cowen boosted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Morgan Stanley downgraded shares of United Therapeutics from an "overweight" rating to an "equal weight" rating and boosted their price objective for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. Argus boosted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Bank of America reduced their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a research note on Thursday, August 1st. Finally, LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 269 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 269 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 14,700 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $964,983.42. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,422 shares of company stock valued at $29,229,828 over the last ninety days. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Up 1.3 %

Shares of UTHR traded up $5.08 during trading hours on Thursday, reaching $402.57. 370,193 shares of the company traded hands, compared to its average volume of 464,712. The stock has a market capitalization of $17.97 billion, a P/E ratio of 17.46, a P/E/G ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $405.98. The business has a fifty day moving average price of $357.42 and a 200-day moving average price of $320.37.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.38 earnings per share. As a group, research analysts predict that United Therapeutics Co. will post 25.57 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.